Targeted Radionuclide Therapies: Lu-177, Ra-223, Y-90 & Radioimmunotherapy

Targeted Radionuclide Therapies & Contamination Decontamination

Targeted radionuclide therapy (TRT) has revolutionized clinical oncology by delivering cytotoxic particulate radiation directly to cellular tumor targets while sparing normal anatomical structures. In contrast to conventional external beam radiotherapy or sealed source brachytherapy, TRT administers unsealed radiopharmaceuticals that circulate systemically or locoregionally. This introduces complex health physics challenges: managing high-energy beta emitters and alpha-emitting decay cascades, mitigating organ-specific radiotoxicities, engineering specialized radiation shielding, executing sensitive contamination monitoring, and establishing rapid-response spill decontamination protocols.

---

Targeted Beta & Alpha Therapeutics: Physical Decay & Dosimetric Characteristics

The clinical efficacy and radiation protection profile of therapeutic radiopharmaceuticals depend directly on their nuclear decay topology, particulate range, linear energy transfer (LET), and physiological clearance pathways.

---

Lutetium-177: Theranostic Mechanics & Nephroprotection

Lutetium-177 ($^{177}\text{Lu}$) is the prototypical "theranostic" radionuclide. Its moderate-energy beta emission ($E_{\beta,\max} = 498\text{ keV}$) provides local soft-tissue crossfire irradiation over a path length of $\sim 1.8\text{ mm}$, sufficient to sterilize microscopic metastatic clusters while minimizing collateral marrow toxicity. Simultaneously, its co-emitted gamma photons at $113\text{ keV}$ ($6.2\%$) and $208\text{ keV}$ ($10.4\%$) closely mirror the imaging photopeaks of standard diagnostic single-photon emission computed tomography (SPECT), enabling direct planar scintigraphy, quantitative pharmacokinetic clearance mapping, and patient-specific internal dosimetry.

$$\begin{aligned} {}^{177}_{71}\text{Lu} &\xrightarrow{\beta^- (100\%)} {}^{177}_{72}\text{Hf}^* \\ {}^{177}_{72}\text{Hf}^* &\xrightarrow{\gamma} {}^{177}_{72}\text{Hf} + \gamma\, (113\text{ keV}, 208\text{ keV}) \end{aligned}$$

Renal Radiotoxicity & Amino Acid Co-Infusion

Peptide receptor radionuclide therapy (PRRT) agents such as $^{177}\text{Lu}$-DOTA-TATE and small-molecule PSMA ligands such as $^{177}\text{Lu}$-PSMA-617 are excreted mainly in urine, much of it within the first day or two. Because these radiolabeled peptides filter freely across the renal glomerulus, they are actively reabsorbed by the endocytic multi-ligand receptor complex (megalin and cubilin) in the brush border of the proximal renal tubules. Unmitigated, the intracellular accumulation of $^{177}\text{Lu}$ delivers massive, dose-limiting localized beta irradiation to the renal cortex, inducing delayed radiation nephropathy, tubular atrophy, and progressive renal failure.

To reduce kidney dose from $^{177}\text{Lu}$-dotatate, the Lutathera label calls for an intravenous infusion of an amino acid solution containing L-lysine ($2.5\%$) and L-arginine ($2.5\%$) started before and continued during and after the dose. (Amino acid infusion is not part of the $^{177}\text{Lu}$-PSMA-617 regimen.) The positively charged basic side chains competitively saturate the anionic binding sites of megalin and cubilin in the proximal tubules, blocking peptide reabsorption and forcing the radiopharmaceutical into the collecting ducts for bladder evacuation. Co-infusion reduces the kidney absorbed dose by roughly $40\%$ to $50\%$, allowing the standard cumulative regimen of $29.6\text{ GBq}$ ($800\text{ mCi}$) in four doses.

---

Radium-223: Targeted Alpha Emitter Dynamics & Excretion Hazard

Radium-223 dichloride ($^{223}\text{RaCl}_2$) is an unsealed targeted alpha therapy approved for castration-resistant prostate cancer with symptomatic osteoblastic bone metastases. As an alkaline earth metal, the divalent cation $\text{Ra}^{2+}$ acts as a biological mimetic of calcium ($\text{Ca}^{2+}$). Following intravenous injection, $^{223}\text{Ra}$ rapidly clears from systemic circulation and forms complexes with bone mineral hydroxyapatite ($[\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2]$) specifically at regions of active osteoblastic osteogenesis surrounding metastatic lesions.

The Alpha Decay Cascade

Upon incorporation into the bone matrix, $^{223}\text{Ra}$ initiates a decay cascade releasing four high-energy alpha particles across five daughter transitions before reaching stable lead-207 ($^{207}\text{Pb}$):

$$\begin{aligned} {}^{223}_{88}\text{Ra} &\xrightarrow{\alpha\, (5.72\text{ MeV}, 11.43\text{ d})} {}^{219}_{86}\text{Rn} \xrightarrow{\alpha\, (6.82\text{ MeV}, 3.96\text{ s})} {}^{215}_{84}\text{Po} \xrightarrow{\alpha\, (7.39\text{ MeV}, 1.78\text{ ms})} {}^{211}_{82}\text{Pb} \\ {}^{211}_{82}\text{Pb} &\xrightarrow{\beta^-\, (1.37\text{ MeV}, 36.1\text{ min})} {}^{211}_{83}\text{Bi} \xrightarrow{\alpha\, (6.62\text{ MeV}, 2.14\text{ min})} {}^{207}_{81}\text{Tl} \xrightarrow{\beta^-\, (1.42\text{ MeV}, 4.77\text{ min})} {}^{207}_{82}\text{Pb}\text{ (stable)} \end{aligned}$$

About $95.3\%$ of the total decay energy ($28.2\text{ MeV}$) is emitted as high-LET alpha radiation ($\sim 80\text{ keV}/\mu\text{m}$). The path length of these alpha particles is less than $100\,\mu\text{m}$ (only $2\text{ to } 10$ cell diameters). This high local ionization density produces complex, unrepairable double-strand DNA cluster breaks in adjacent tumor cells and osteoclasts, while sparing the adjacent hematopoietically active bone marrow stroma located further away. Consequently, severe myelosuppression is rare compared to broad-spectrum beta therapies.

Radiation Protection & Excretion Profile

• External Exposure: Photons carry only about $1.1\%$ of the decay energy (low-yield gammas such as $154\text{ keV}$ and $269\text{ keV}$). With the label dose of $55\text{ kBq/kg}$ (about $4\text{ MBq}$, $0.1\text{ mCi}$, for a 75 kg patient), the external dose rate is very low, and patients can be released immediately under 10 CFR 35.75.
• Internal Contamination Hazard: The Xofigo label reports that excretion is mainly through the intestine: about $13\%$ of the activity appears in feces and about $2\%$ in urine within 48 hours, and about $63\%$ has been excreted from the body within 7 days (decay corrected), with no evidence of hepatobiliary excretion; the drug is thought to pass into the gut by secretion through the intestinal wall. The health physics operational hazard is almost exclusively related to internal alpha contamination via fecal cross-contamination. Patient instructions must emphasize rigorous fecal hygiene: double-flushing toilets, using dedicated bathroom facilities, wearing disposable gloves to handle soiled clothing, and laundering contaminated linens separately.

---

Yttrium-90 Microspheres: Bremsstrahlung Physics & Radioembolization Dosimetry

Selective internal radiation therapy (SIRT), or transcatheter arterial radioembolization (TARE), treats unresectable hepatocellular carcinoma (HCC) and hepatic colorectal metastases using Yttrium-90 ($^{90}\text{Y}$) microspheres. Two commercial formulations dominate clinical practice: non-biodegradable glass microspheres (TheraSphere, $20\text{--}30\,\mu\text{m}$ diameter, high specific activity $\sim 2,500\text{ Bq}$/sphere) and biocompatible resin microspheres (SIR-Spheres, $20\text{--}60\,\mu\text{m}$ diameter, lower specific activity $\sim 50\text{ Bq}$/sphere). Microspheres are delivered via transfemoral catheterization directly into the hepatic arterial branches feeding the hypervascular tumor.

Yttrium-90 decays with a half-life of $64.1\text{ hours}$ via pure beta emission ($E_{\beta,\max} = 2.28\text{ MeV}$, mean $E_\beta = 0.93\text{ MeV}$) directly to the ground state of zirconium-90 ($^{90}\text{Zr}$):

${}^{90}_{39}\text{Y} \xrightarrow{\beta^- (100\%)} {}^{90}_{40}\text{Zr} + \bar{\nu}_e \quad (E_{\beta,\max} = 2.28\text{ MeV})$

Bremsstrahlung Generation & Shielding Engineering

When high-energy beta particles decelerate in the Coulomb field of atomic nuclei, they lose energy via radiative collisions, producing a continuous spectrum of bremsstrahlung X-rays. The radiative stopping power and fractional kinetic energy converted into bremsstrahlung ($f_{\text{rad}}$) are proportional to the atomic number ($Z$) of the absorber and the maximum beta kinetic energy ($E_{\beta,\max}$ in $\text{MeV}$):

$f_{\text{rad}} \approx 3.5 \times 10^{-4} \times Z \times E_{\beta,\max}$

Consider the contrast between shielding $^{90}\text{Y}$ ($E_{\beta,\max} = 2.28\text{ MeV}$) with elemental lead ($Z = 82$) versus transparent acrylic/polymethyl methacrylate (PMMA, $Z_{\text{eff}} \approx 6.5$):

• Lead ($Z = 82$): $f_{\text{rad}} \approx 3.5 \times 10^{-4} \times 82 \times 2.28 \approx 0.0654$ ($6.54\%$ of beta energy converted to bremsstrahlung).
• Acrylic ($Z_{\text{eff}} = 6.5$): $f_{\text{rad}} \approx 3.5 \times 10^{-4} \times 6.5 \times 2.28 \approx 0.0052$ ($0.52\%$ converted to bremsstrahlung, a $> 12\times$ reduction).

If high-activity $^{90}\text{Y}$ vials ($> 10\text{ GBq}$) are placed directly inside an unlined lead shield, high-energy betas striking the high-$Z$ lead nuclei produce an intense flux of penetrating bremsstrahlung photons, sharply increasing extremity and whole-body exposure. Consequently, the primary engineering rule for high-energy beta shielding requires a two-layer composite shield: an inner layer of low-$Z$ acrylic (Lucite or Plexiglas) of thickness exceeding the maximum beta range in PMMA (minimum $\ge 10\text{ to } 12\text{ mm}$) to absorb all primary electrons with minimal radiative loss, surrounded by an outer secondary shell of thin lead ($2\text{ to } 3\text{ mm}$) to attenuate the residual low-yield bremsstrahlung.

Pre-Treatment Workup: Lung Shunt Fraction (LSF)

Hepatic malignancies often establish pathological arteriovenous shunts that bypass the hepatic sinusoids, diverting arterial blood into the hepatic veins, inferior vena cava, and pulmonary capillary bed. Microspheres escaping through these shunts lodge in pulmonary capillaries, causing radiation pneumonitis. Prior to $^{90}\text{Y}$ therapy, an interventional radiologist infuses $150\text{ to } 200\text{ MBq}$ ($4\text{ to } 5\text{ mCi}$) of technetium-99m macroaggregated albumin ($^{99\text{m}}\text{Tc}$-MAA, particle size $10\text{--}90\,\mu\text{m}$) into the target hepatic artery. Planar gamma camera or SPECT/CT imaging calculates the Lung Shunt Fraction (LSF):

$\text{LSF} = \frac{C_{\text{lung}}}{C_{\text{lung}} + C_{\text{liver}}}$

where $C_{\text{lung}}$ and $C_{\text{liver}}$ represent the geometric mean counts in the pulmonary and hepatic regions of interest, corrected for background and tissue attenuation. Under standard MIRD schema, assuming uniform distribution across a standard $1.0\text{ kg}$ lung mass ($M_{\text{lung}}$), the absorbed dose delivered to the lungs ($D_{\text{lung}}$) from an administered activity $A_{\text{admin}}$ (in $\text{GBq}$) is:

$D_{\text{lung}} (\text{Gy}) = \frac{A_{\text{admin}} (\text{GBq}) \times \text{LSF} \times 50\text{ J/GBq}}{M_{\text{lung}} (\text{kg})}$

(Note: Complete decay of $1\text{ GBq}$ of $^{90}\text{Y}$ yields $\tilde{A} = 10^9\text{ Bq} \times (64.1 \times 3600\text{ s}) / \ln(2) = 3.33 \times 10^{14}\text{ disintegrations}$, which at $\bar{E}_\beta = 0.93\text{ MeV} = 1.49 \times 10^{-13}\text{ J}$ equals $\approx 50\text{ Joules}$).

For glass microspheres (TheraSphere), the lung absorbed dose should not exceed $30\text{ Gy}$ in a single administration or $50\text{ Gy}$ cumulatively. For resin microspheres (SIR-Spheres), treatment is generally not given when the lung shunt fraction exceeds $20\%$, and the activity is reduced for intermediate shunt fractions.

---

Radioimmunotherapy and Other Targeted Agents

Radioimmunotherapy (RIT) attaches a therapeutic radionuclide to a monoclonal antibody. The model US agent is $^{90}\text{Y}$-ibritumomab tiuxetan (Zevalin), an anti-CD20 antibody for B-cell non-Hodgkin lymphoma. Its label regimen is:

• Day 1: rituximab $250\text{ mg/m}^2$ infusion (to clear circulating B cells and improve biodistribution).
• Day 7, 8, or 9: a second rituximab $250\text{ mg/m}^2$ infusion, then within 4 hours $^{90}\text{Y}$-Zevalin at $14.8\text{ MBq/kg}$ ($0.4\text{ mCi/kg}$) if platelets are at least $150{,}000/\text{mm}^3$, or $11.1\text{ MBq/kg}$ ($0.3\text{ mCi/kg}$) for relapsed or refractory patients with platelets of $100{,}000$–$149{,}000/\text{mm}^3$; patients below $100{,}000$ are not treated.
• Maximum: $1{,}184\text{ MBq}$ ($32\text{ mCi}$) regardless of body weight.

Because $^{90}\text{Y}$ is a pure beta emitter, the radiation safety issues are the same as for microspheres: acrylic syringe shields, bremsstrahlung awareness, and attention to contamination. The dose-limiting toxicity is myelosuppression, which is why the activity is scaled to platelet count. The $^{131}\text{I}$-labeled antibody tositumomab (Bexxar) was withdrawn from the US market in 2014.

Other approved regimens a health physicist should recognize:

Each of these therapies needs a written directive under 10 CFR 35.40, and the activity is verified before administration under 35.63.